Download full-text PDF

Source
http://dx.doi.org/10.1093/jac/dkq044DOI Listing

Publication Analysis

Top Keywords

stability meropenem
4
meropenem doripenem
4
doripenem solutions
4
solutions administration
4
administration continuous
4
continuous infusion
4
stability
1
doripenem
1
solutions
1
administration
1

Similar Publications

Non-fermenting Gram-negative bacteria are resistant to most antibiotics, due to the production of enzymes such as NDM-1. Faced with this challenge, computational methods have become essential for the design of NDM-1 carbapenemase inhibitors, optimizing both the time and cost of the development of new lead molecules. In this study, molecular docking and molecular dynamics (MD) simulations were performed in order to identify effective inhibitors against the NDM-1 enzyme.

View Article and Find Full Text PDF

An a (AEF) is a rare but life-threatening condition where an abnormal connection forms between the aorta and the gastrointestinal tract, most commonly the duodenum. It can be primary (arising spontaneously due to an aortic aneurysm or infection) or secondary (complicating prior vascular surgery). Immediate recognition and surgical intervention are critical to manage severe gastrointestinal bleeding and prevent fatal outcomes.

View Article and Find Full Text PDF

Objective: Meropenem degradation poses a challenge to continuous infusion (CI) implementation. However, data about the impact of degradation on the probability of target attainment (PTA) of meropenem has been limited. This study evaluated the stability of meropenem brands and the consequence of in-bottle degradation on PTA in different environmental scenarios.

View Article and Find Full Text PDF

Acquired Factor XIII (FXIII) deficiency is a rare condition often associated with underlying medical conditions or medications. We present a case of a 23-year-old male, who presented with prolonged bleeding from a traumatic ulcer site on his left leg. Initial laboratory investigations revealed a severe deficiency in FXIII activity (30%) and antigen levels (25%), with no evidence of congenital disorders or other underlying pathologies.

View Article and Find Full Text PDF

Target-controlled dialysis for antibiotics (TCD-ABx).

Intensive Care Med Exp

November 2024

Department of Anaesthesiology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.

Article Synopsis
  • * Five antibiotics were tested in an in vitro model of continuous veno-venous hemodialysis, simulating different patient scenarios to see how drug levels could be adjusted effectively during dialysis.
  • * Results indicate that target-controlled dialysis can reliably adjust and maintain antibiotic concentrations at desired therapeutic levels throughout the treatment, suggesting it may improve patient outcomes in critical care settings.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!